Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BDX 
Becton Dickinson and Company (BDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 64.90B USD | Price to earnings Ratio 38.12 | 1Y Target Price 276.57 |
Price to earnings Ratio 38.12 | 1Y Target Price 276.57 | ||
Volume (30-day avg) 1894097 | Beta 0.38 | 52 Weeks Range 215.84 - 250.85 | Updated Date 04/1/2025 |
52 Weeks Range 215.84 - 250.85 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 1.74% | Basic EPS (TTM) 5.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.37% | Operating Margin (TTM) 15.27% |
Management Effectiveness
Return on Assets (TTM) 3.7% | Return on Equity (TTM) 6.84% |
Valuation
Trailing PE 38.12 | Forward PE 16.34 | Enterprise Value 83801239534 | Price to Sales(TTM) 3.14 |
Enterprise Value 83801239534 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 4.06 | Enterprise Value to EBITDA 17.26 | Shares Outstanding 287135008 | Shares Floating 286446296 |
Shares Outstanding 287135008 | Shares Floating 286446296 | ||
Percent Insiders 0.56 | Percent Institutions 93.6 |
Analyst Ratings
Rating 4.33 | Target Price 278.8 | Buy 6 | Strong Buy 9 |
Buy 6 | Strong Buy 9 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Becton Dickinson and Company
Company Overview
History and Background
Becton Dickinson and Company (BD) was founded in 1897. It started as a medical supply company and has evolved into a global medical technology company. Key milestones include the development of the first mass-produced hypodermic syringe and needle, expansion into diagnostics, and strategic acquisitions to broaden its portfolio.
Core Business Areas
- BD Medical: Produces medical devices such as syringes, needles, and medication delivery systems used in hospitals and clinics.
- BD Life Sciences: Focuses on diagnostics, biosciences, and preanalytical systems used in research and clinical laboratories.
- BD Interventional: Offers products for vascular, urology, oncology, and surgical specialties.
Leadership and Structure
The CEO is Thomas Polen. The company has a hierarchical organizational structure with various business units reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- BD Alaris System: A comprehensive infusion management system. Competitors include Baxter and ICU Medical. Market share data is variable but BD holds a leading position in the infusion pump market. Not available exact revenue but it is a major product line.
- BD Vacutainer: A blood collection system used globally. Competitors include Greiner Bio-One and Sekisui Diagnostics. BD Vacutainer is a market leader. Not available exact revenue but it is a major product line.
- BD Pyxis: An automated medication dispensing system. Competitors include Omnicell and Capsa Healthcare. BD Pyxis is a major product line. Not available exact revenue but it is a major product line.
Market Dynamics
Industry Overview
The medical technology industry is driven by innovation, aging populations, and increasing healthcare spending. Regulatory approvals and reimbursement policies are key factors.
Positioning
BD is a leading player in the medical technology industry, known for its broad product portfolio, global reach, and strong brand reputation. Its competitive advantages include its established customer base, technological innovation, and efficient supply chain.
Total Addressable Market (TAM)
The global medical device market is estimated to be over $500 billion. BD is well positioned to capture a significant portion of this TAM due to its diverse product offerings and global presence.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong brand reputation
- Established customer base
- Innovation capabilities
Weaknesses
- Exposure to regulatory risks
- Integration challenges from acquisitions
- Dependence on hospital spending
- Vulnerable to supply chain disruptions
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Partnering with healthcare providers
Threats
- Intense competition
- Pricing pressures
- Technological obsolescence
- Economic downturns
- Adverse regulatory changes
Competitors and Market Share
Key Competitors
- DHR
- MMM
- TMO
- SYK
Competitive Landscape
BD competes with other large medical technology companies on price, innovation, and product quality. BD's broad product portfolio and global presence give it a competitive advantage, but competitors may have strengths in specific market segments.
Major Acquisitions
Bard
- Year: 2017
- Acquisition Price (USD millions): 24000
- Strategic Rationale: Expanded BD's product portfolio in vascular, urology, oncology, and surgical specialties.
Growth Trajectory and Initiatives
Historical Growth: Data intentionally withheld as this exceeds my current capacity to retrieve this information. Placeholder to demonstrate JSON format only
Future Projections: Data intentionally withheld as this exceeds my current capacity to retrieve this information. Placeholder to demonstrate JSON format only
Recent Initiatives: Data intentionally withheld as this exceeds my current capacity to retrieve this information. Placeholder to demonstrate JSON format only
Summary
Becton Dickinson is a major player in the medical technology industry, boasting a diverse product range and global reach. Its acquisitions have strengthened its position, however integration challenges are prevalent. The company must continue to innovate and adapt to changing healthcare landscapes and regulations. Despite competition, BD's brand and customer base provide a solid foundation.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
DHR
Danaher Corporation
DHR
Danaher Corporation
MMM
3M Company
MMM
3M Company
SYK
Stryker Corporation
SYK
Stryker Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Becton Dickinson and Company
Exchange NYSE | Headquaters Franklin Lakes, NJ, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Chairman Mr. Thomas E. Polen Jr. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 70000 | Website https://www.bd.com |
Full time employees 70000 | Website https://www.bd.com | ||
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.